BE631490A - - Google Patents
Info
- Publication number
- BE631490A BE631490A BE631490DA BE631490A BE 631490 A BE631490 A BE 631490A BE 631490D A BE631490D A BE 631490DA BE 631490 A BE631490 A BE 631490A
- Authority
- BE
- Belgium
- Prior art keywords
- composition according
- compound
- parts
- sep
- animals
- Prior art date
Links
- 239000000203 mixture Substances 0.000 claims description 115
- 150000001875 compounds Chemical class 0.000 claims description 34
- 241000283898 Ovis Species 0.000 claims description 27
- 241001465754 Metazoa Species 0.000 claims description 26
- 229950000688 Phenothiazine Drugs 0.000 claims description 25
- WJFKNYWRSNBZNX-UHFFFAOYSA-N Phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 claims description 24
- 239000000470 constituent Substances 0.000 claims description 16
- 239000002270 dispersing agent Substances 0.000 claims description 7
- 239000011780 sodium chloride Substances 0.000 claims description 7
- UIIMBOGNXHQVGW-UHFFFAOYSA-M NaHCO3 Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- 229910052717 sulfur Inorganic materials 0.000 claims description 5
- VZGDMQKNWNREIO-UHFFFAOYSA-N Carbon tetrachloride Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 claims description 4
- RAXXELZNTBOGNW-UHFFFAOYSA-N Imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 125000001424 substituent group Chemical group 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 235000015278 beef Nutrition 0.000 claims description 3
- 230000000875 corresponding Effects 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 3
- 235000010755 mineral Nutrition 0.000 claims description 3
- 239000011707 mineral Substances 0.000 claims description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 3
- 239000001187 sodium carbonate Substances 0.000 claims description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 3
- 239000004094 surface-active agent Substances 0.000 claims description 3
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 2
- 125000002541 furyl group Chemical group 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims description 2
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- 125000004076 pyridyl group Chemical group 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 125000004434 sulfur atoms Chemical group 0.000 claims description 2
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 150000003851 azoles Chemical class 0.000 claims 1
- 235000019804 chlorophyll Nutrition 0.000 claims 1
- 229930002875 chlorophylls Natural products 0.000 claims 1
- 229910052751 metal Inorganic materials 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- 125000004433 nitrogen atoms Chemical group N* 0.000 claims 1
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 claims 1
- 150000002990 phenothiazines Chemical group 0.000 claims 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 231100000167 toxic agent Toxicity 0.000 claims 1
- 239000003440 toxic substance Substances 0.000 claims 1
- 229920001098 polystyrene-block-poly(ethylene/propylene) Polymers 0.000 description 104
- 230000000694 effects Effects 0.000 description 31
- 208000006968 Helminthiasis Diseases 0.000 description 14
- 201000001181 parasitic helminthiasis infectious disease Diseases 0.000 description 14
- 230000000507 anthelmentic Effects 0.000 description 13
- 239000003814 drug Substances 0.000 description 13
- 229940079593 drugs Drugs 0.000 description 13
- JYZIHLWOWKMNNX-UHFFFAOYSA-N Benzimidazole Chemical compound C1=C[CH]C2=NC=NC2=C1 JYZIHLWOWKMNNX-UHFFFAOYSA-N 0.000 description 10
- 239000000654 additive Substances 0.000 description 10
- 230000000996 additive Effects 0.000 description 10
- 150000001556 benzimidazoles Chemical class 0.000 description 9
- 239000006185 dispersion Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 241000894007 species Species 0.000 description 7
- 239000000047 product Substances 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 5
- 230000002588 toxic Effects 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000007859 condensation product Substances 0.000 description 4
- 238000000227 grinding Methods 0.000 description 4
- 239000008247 solid mixture Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- DWYHDSLIWMUSOO-UHFFFAOYSA-N 2-phenyl-1H-benzimidazole Chemical compound C1=CC=CC=C1C1=NC2=CC=CC=C2N1 DWYHDSLIWMUSOO-UHFFFAOYSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 229940058303 antinematodal Benzimidazole derivatives Drugs 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- -1 heterocyclic radical Chemical class 0.000 description 3
- 230000003000 nontoxic Effects 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- IAYPIBMASNFSPL-UHFFFAOYSA-N oxane Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- 159000000000 sodium salts Chemical class 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- 239000005995 Aluminium silicate Substances 0.000 description 2
- PZZYQPZGQPZBDN-UHFFFAOYSA-N Aluminium silicate Chemical compound O=[Al]O[Si](=O)O[Al]=O PZZYQPZGQPZBDN-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010061217 Infestation Diseases 0.000 description 2
- 241000244206 Nematoda Species 0.000 description 2
- 235000012211 aluminium silicate Nutrition 0.000 description 2
- 201000009910 diseases by infectious agent Diseases 0.000 description 2
- 230000001586 eradicative Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L mgso4 Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- AGIJRRREJXSQJR-UHFFFAOYSA-N 2H-thiazine Chemical compound N1SC=CC=C1 AGIJRRREJXSQJR-UHFFFAOYSA-N 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- CIFIVCCKVZFJFT-UHFFFAOYSA-N 4-(4-chlorophenyl)-N-(2-imidazol-1-yl-1-phenylethyl)benzamide Chemical group C1=CC(Cl)=CC=C1C1=CC=C(C(=O)NC(CN2C=NC=C2)C=2C=CC=CC=2)C=C1 CIFIVCCKVZFJFT-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241001247986 Calotropis procera Species 0.000 description 1
- 210000004534 Cecum Anatomy 0.000 description 1
- 241000893172 Chabertia Species 0.000 description 1
- 241001126268 Cooperia Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N Ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- CYTYCFOTNPOANT-UHFFFAOYSA-N Ethylene tetrachloride Chemical group ClC(Cl)=C(Cl)Cl CYTYCFOTNPOANT-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 210000001035 Gastrointestinal Tract Anatomy 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 210000000936 Intestines Anatomy 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 1
- 241001137882 Nematodirus Species 0.000 description 1
- SNQQPOLDUKLAAF-UHFFFAOYSA-N Nonylphenol Chemical compound CCCCCCCCCC1=CC=CC=C1O SNQQPOLDUKLAAF-UHFFFAOYSA-N 0.000 description 1
- 235000007959 Psilotum nudum Nutrition 0.000 description 1
- 229940119265 Sepp Drugs 0.000 description 1
- WJCNZQLZVWNLKY-UHFFFAOYSA-N Tiabendazole Chemical compound S1C=NC(C=2NC3=CC=CC=C3N=2)=C1 WJCNZQLZVWNLKY-UHFFFAOYSA-N 0.000 description 1
- 241000822135 Ula Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000007765 cera alba Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 125000000068 chlorophenyl group Chemical group 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000001079 digestive Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- UYJUZNLFJAWNEZ-UHFFFAOYSA-N fuberidazole Chemical compound C1=COC(C=2NC3=CC=CC=C3N=2)=C1 UYJUZNLFJAWNEZ-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 150000002829 nitrogen Chemical group 0.000 description 1
- 244000045947 parasites Species 0.000 description 1
- 230000003071 parasitic Effects 0.000 description 1
- 230000001717 pathogenic Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000546 pharmaceutic aid Substances 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 230000003330 sporicidal Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000002195 synergetic Effects 0.000 description 1
- 229950011008 tetrachloroethylene Drugs 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Publications (1)
Publication Number | Publication Date |
---|---|
BE631490A true BE631490A (de) |
Family
ID=199947
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BE631490D BE631490A (de) |
Country Status (1)
Country | Link |
---|---|
BE (1) | BE631490A (de) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0194529A2 (de) * | 1985-03-01 | 1986-09-17 | Gödecke Aktiengesellschaft | Verwendung von 2-(Aminophenyl)-benzimidazol-Derivaten für die Herstellung von Arzneimitteln zur Bekämpfung maligner und nicht maligner proliferativer sowie autoimmuner Erkrankungen und zur Immunsuppression bei Transplantationen |
EP2251010A1 (de) * | 2009-05-08 | 2010-11-17 | Sygnis Bioscience GmbH & Co. KG | Verwendungen von Thiabendazol und Derivaten davon zur Behandlung neurologischer Leiden |
-
0
- BE BE631490D patent/BE631490A/fr unknown
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0194529A2 (de) * | 1985-03-01 | 1986-09-17 | Gödecke Aktiengesellschaft | Verwendung von 2-(Aminophenyl)-benzimidazol-Derivaten für die Herstellung von Arzneimitteln zur Bekämpfung maligner und nicht maligner proliferativer sowie autoimmuner Erkrankungen und zur Immunsuppression bei Transplantationen |
EP0194529A3 (en) * | 1985-03-01 | 1990-01-17 | Godecke Aktiengesellschaft | Use of 2-(aminophenyl)-benzimidazole derivatives in the preparation of medicaments for combating malign and non-malign proliferative as well as auto-immune diseases and in immunosuppression in transplantations |
EP2251010A1 (de) * | 2009-05-08 | 2010-11-17 | Sygnis Bioscience GmbH & Co. KG | Verwendungen von Thiabendazol und Derivaten davon zur Behandlung neurologischer Leiden |
WO2010127878A3 (en) * | 2009-05-08 | 2011-02-03 | Sygnis Bioscience Gmbh & Co. Kg | Use of thiabendazole and derivatives thereof for the theraphy of neurological conditions |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1513837B1 (de) | Thiazolderivate als phosphodiesterase iv-inhibtoren | |
US7396838B2 (en) | Use of 1H-indol-3-yl-2-oxoacetamide compounds | |
EP1223933A2 (de) | Fünfgliedrige-heteroringderivate und ihre verwendung als monoaminoxidase-inhibitoren | |
CA2466813A1 (fr) | Derives de benzimidazoles et leur utilisation comme inhibiteurs de proteine kinase kdr | |
CA2153341A1 (fr) | Application de la carbamazepine et de l'oxcarbazepine dans le traitement de la maladie de parkinson et des syndromes parkinsoniens | |
TW200307535A (en) | Therapeutic agent for cancer | |
CN1413105A (zh) | 新的治疗方法 | |
FR2962649A1 (fr) | Traitement d'une pathologie liee a un effet excessif du tnf par un compose de benzene sulfonamide | |
CA2889326A1 (en) | Therapeutic or prophylactic agent for tumor lysis syndrome | |
DE60030164T2 (de) | 3-Heteroarylidenyl-2-Indolinon Derivate für die Modulierung der Aktivität einer Proteinkinase und für die Verwendung bei der Chemotherapie von Krebs | |
EP0808166A1 (de) | Arzneimittel zur behandlung von obsessiv-impulsiven erkrankungen wie schlafsapnoe, sexualfunktionsstörungen, erbrechen und reisekrankheit | |
DE60030654T2 (de) | Verwendung von Lasofoxifen | |
BE631490A (de) | ||
DE1470104A1 (de) | Substituierte Benzazole und Verfahren zu deren Herstellung | |
FR2580642A1 (fr) | 5-pyrimidinecarboxamides et traitement de la leucemie et des tumeurs en les utilisant | |
FR2466988A1 (fr) | Compositions antifongiques synergiques, utiles notamment contre candida albicans | |
CN105658645A (zh) | 作为mpge-1抑制剂的哌啶基苯并咪唑衍生物 | |
CA2832866A1 (fr) | Derives de l'acadesine, produits et compositions les comprenant, leurs utilisations therapeutiques et leurs procedes de synthese | |
CN104271140B (zh) | I型和ii型糖尿病的治疗 | |
JP6085706B1 (ja) | 抗トリトリコモナス剤 | |
DE3028927C2 (de) | Azoverbindungen enthaltendes pharmazeutisches Mittel | |
EP3045169A1 (de) | Rezeptur für eine wässrige lösung und herstellungsverfahren dafür | |
KR20230159375A (ko) | 의약에서 사용하기 위한 4-클로로-n-[2-[(4-클로로페닐)메틸]-3-옥소-1,2,4-티아디아졸-5-일]벤즈아미드 | |
FR2731618A1 (fr) | Composition ophtalmique topique comprenant un derive de 2-(4-(azolylbutyl)-piperazinyl-methyl)-benzimidazole, notamment pour le traitement de la conjonctivite allergique | |
TW202408499A (zh) | 降低血中肌肉生長抑制素之藥劑 |